MannKind says FDA approves Afrezza inhaled mealtime insulin for children aged 6 and older

MannKind Corporation

MannKind Corporation

MNKD

0.00
  • FDA cleared MannKind’s Afrezza inhaled mealtime insulin for children and adolescents aged 6+ with type 1 or type 2 diabetes.
  • Label expansion adds a pediatric market to Afrezza, previously authorized only for adults since 2014.
  • Decision was backed by the Phase 3 INHALE-1 pediatric study, supported by longer-term inhaled insulin safety data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605291230PRIMZONEFULLFEED9728907) on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.